In vivo CAR-37 mediated tumor clearance of a MCL model. (A) Experiment schematic: NSG mice were injected IV with 1 × 10⁶ JEKO-1(CBG⁻GFP) cells and monitored by BLI for tumor burden at different points. At day 0, mice were randomly assigned on the basis of tumor burden (BLI) to receive 2 × 10⁶ control T cells (UTD), CAR-37, or CAR-19. (B) Representative bioluminescent images of JEKO-1 growth over time. (C) Average flux (photons/s) of whole mice in the 3 groups at different points. Graph is representative of 2 experiments with 5 mice per group, conducted with CAR T cells obtained from 2 different healthy donors. Mean ± SD shown. ***P < .001 by 2-way analysis of variance. (D) Absolute numbers of CAR T cells were monitored by bleeding and flow cytometric detection. Absolute CAR T-cell counts in peripheral blood at day 14 after CAR T injection are shown (Student t test, *P < .05).